Roche to increase its payroll in Switzerland by 0.9 percent

Basel, 01 December 2016

Roche is increasing the payroll for its workforce of over 14,000 employees in Switzerland by 0.9 percent with effect from 1 April 2017. This latest increase acknowledges the great commitment of our employees, taking into account the company’s positive performance in a challenging market environment in Europe and Switzerland. The increase also reflects the development of the cost of living as well as market salaries and wages for comparable employment.

Over the last few weeks, the Roche Employees Association in Switzerland (AVR) and the Roche Basel Works Council (AKR) held discussions at Roche regarding the adjustment of the 2017 payroll. The result announced today was endorsed by all parties following fair, focused and constructive negotiations.

The 0.9 percent payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2017.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a

frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015

employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.